A snapshot of Binance's perpetual Bitcoin order book revealed a $6.18 million bid at the price of $77,189, representing about 80 BTC. This bid price is slightly below the market midpoint of $77,280, indicating strong buy-side liquidity just below current market levels. Total bids across nearby prices reached approximately $50.54 million, while asks were about $36.77 million, showing a bid-side depth advantage of $13.77 million or 15.77%. These figures provide insight into market liquidity and potential price support levels, though it is unclear if the highlighted bid was executed or remained open.
The Binance perpetual Bitcoin order book snapshot shows a $6.18 million bid at $77,189, slightly below the market midpoint of $77,280, with total bids near $50.54 million and asks around $36.77 million as of Oct 31, 2026 14:41 WIB. For readers following major cryptocurrencies on Pluang, 30 of 50 priced assets rose while 19 fell today. Notable movers include YFI at Rp34.477.213 (+6.20%, 0% Sell / 100% Buy), CRV at Rp5.245 (+5.41%, 11% Sell / 89% Buy), and COTI at Rp174 (+4.97%, 34% Sell / 66% Buy).
Honeywell Aerospace is rated Buy at $160 due to a strong $19.3 billion order backlog and expected improvements in production. Current revenue growth is limited by supply chain issues, but order growth and supplier efforts support a positive outlook o...
Avalanche's native token AVAX traded at $8.48 on Binance spot on October 31, marking a 1.28% decrease over the past 24 hours. AVAX is important as it is used for paying transaction fees and staking within the Avalanche Primary Network. This price mov...
The Cardano Foundation has joined Switzerland's Capital Markets and Technology Association (CMTA), which recognized Cardano's CIP-0113 token standard as equivalent to its own framework for certifying tokenized shares. This allows issuers to tokenize ...
Alphabet's stock fell 12% after missing non-operating EPS expectations and showing slower Search growth, causing its worst single-day drop. Despite this, the core business remains strong with Cloud revenue doubling and a $561 billion backlog supporti...
Novartis is rated Hold with a 12-month price target of $141.81, suggesting a 12% downside from current levels. The company faces near-term challenges on some products, but its drug development pipeline could support growth over the longer term. Valua...
